Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

Blood - Tập 98 - Trang 548-553 - 2001
Richard M. Stone, Deborah T. Berg, Stephen L. George, Richard K. Dodge, Paolo A. Paciucci, Philip P. Schulman, Edward J. Lee, Joseph O. Moore, Bayard L. Powell, Maria R. Baer, Clara D. Bloomfield, Charles A. Schiffer

Tóm tắt

AbstractThe treatment of older patients with acute myeloid leukemia (AML) remains unsatisfactory, with complete remission (CR) achieved in only approximately 50% and long-term disease-free survival in 10% to 20%. Three hundred eighty-eight patients (60 years of age and older) with newly diagnosed de novo AML were randomly assigned to receive placebo (P) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or GM in a double-blind manner, beginning 1 day after the completion of 3 days of daunorubicin and 7 days of cytarabine therapy. No differences were found in the rates of leukemic regrowth, CR, or infectious complications in either arm. Of 205 patients who achieved CR, 169 were medically well and were randomized to receive cytarabine alone or a combination of cytarabine and mitoxantrone. With a median follow-up of 7.7 years, the median disease-free survival times were 11 months and 10 months for those randomized to cytarabine or cytarabine/mitoxantrone, respectively. Rates of relapse, excluding deaths in CR, were 77% for cytarabine and 82% for cytarabine/mitoxantrone. Induction randomization had no effect on leukemic relapse rate or remission duration in either postremission arm. Because cytarabine/mitoxantrone was more toxic and no more effective than cytarabine, it was concluded that this higher-dose therapy had no benefit in the postremission management of older patients with de novo AML. These results suggest the need to develop novel therapeutic strategies for these patients.

Tài liệu tham khảo

Heath, 1996, Epidemiology and hereditary aspects of acute leukemia., Neoplastic Diseases of the Blood., 177 Schiffer, 1989, Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia., Blood., 73, 263, 10.1182/blood.V73.1.263.263 Pedersen-Bjergaard, 1990, Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia., Blood., 76, 1083, 10.1182/blood.V76.6.1083.1083 Levine, 1992, Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure., Semin Oncol., 19, 47 Leith, 1997, Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study., Blood., 89, 3323, 10.1182/blood.V89.9.3323 Stone, 1995, Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia., N Engl J Med., 332, 1671, 10.1056/NEJM199506223322503 Rowe, 1995, A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)., Blood., 86, 457, 10.1182/blood.V86.2.457.bloodjournal862457 Zittoun, 1996, Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group., J Clin Oncol., 14, 2150, 10.1200/JCO.1996.14.7.2150 Lowenberg, 1997, Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group., Blood., 90, 2952 Godwin, 1998, A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study., Blood., 91, 3607, 10.1182/blood.V91.10.3607 Heil, 1997, A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia., Blood., 90, 4710, 10.1182/blood.V90.12.4710 Dombret, 1995, A controlled study of recombinant human granulocyte colony-stimulating factor in patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group., N Engl J Med., 332, 1678, 10.1056/NEJM199506223322504 Mayer, 1994, Intensive post-remission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B., N Engl J Med., 331, 896, 10.1056/NEJM199410063311402 Rees, 1986, Principal results of the Medical Research Council's 8th acute myeloid leukemia trial., Lancet., 2, 1236, 10.1016/S0140-6736(86)92674-7 Cassileth, 1984, A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia., Blood., 63, 843, 10.1182/blood.V63.4.843.843 Bloomfield, 1985, Postremission therapy in acute myeloid leukemia., J Clin Oncol., 3, 1570, 10.1200/JCO.1985.3.12.1570 Cassileth, 1992, Varying intensity of postremission therapy in acute myeloid leukemia., Blood., 79, 1924, 10.1182/blood.V79.8.1924.1924 Paciucci, 1990, Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia., Am J Hematol., 35, 22, 10.1002/ajh.2830350106 Bennett, 1985, Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group., Ann Intern Med., 103, 620, 10.7326/0003-4819-103-4-620 Bennett, 1991, Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-MO)., Br. J Haematol., 78, 325, 10.1111/j.1365-2141.1991.tb04444.x Mitelman, 1995, ISCN: An International System for Human Cytogenetic Nomenclature. Baer, 1997, Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22)., Blood., 90, 1643, 10.1182/blood.V90.4.1643 Cheson, 1990, Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia., J Clin Oncol., 8, 813, 10.1200/JCO.1990.8.5.813 Kaplan, 1958, Nonparametric estimation from incomplete observations., J Am Stat Assoc., 53, 457, 10.1080/01621459.1958.10501452 Peto, 1977, Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples., Br J Cancer., 35, 1, 10.1038/bjc.1977.1 Simon, 1982, Nonparametric confidence limits for survival probabilities and median survival time., Cancer Treat Rep., 66, 37 Brookmeyer, 1982, A confidence interval for the median survival time., Biometrics., 38, 29, 10.2307/2530286 Cox, 1972, Regression models and life tables., J R Stat Soc., B34, 187 Armitage, 1971, Statistical Methods in Medical Research. Stone, 1993, The approach to the elderly patient with acute myeloid leukemia., Hematol Oncol Clin North Am., 7, 65, 10.1016/S0889-8588(18)30258-2 Bloomfield, 1998, Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype., Cancer Res., 58, 4173 Raspadori, 1998, CD56 expression in acute myeloid leukemia identifies patients with poor clinical outcome [abstract]., Blood., 92, 2498 Suzuki, 1997, CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity., Blood., 90, 2417, 10.1182/blood.V90.6.2417 Seymour, 1994, Investigation of karyotypic, morphologic, and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56)., Leukemia., 8, 823 Rubin, 1992, Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia., J Clin Oncol., 10, 948, 10.1200/JCO.1992.10.6.948 Lowenberg, 1998, Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy: the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group., J Clin Oncol., 16, 872, 10.1200/JCO.1998.16.3.872 Moore, 1997, Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022., Blood., 89, 780, 10.1182/blood.V89.3.780 List, 1993, Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia., J Clin Oncol., 11, 1652, 10.1200/JCO.1993.11.9.1652 Lee, 1999, Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420., J Clin Oncol., 17, 2831, 10.1200/JCO.1999.17.9.2831
Thông tin
Thông tin xuất bản

Blood

Tập 98

548-553

Thông tin tác giả